Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenjun Wu

Showing results (361-370 of 454) with videos related to

Pageof 46
Sort By:
Bone Marrow Transplantation|June 1, 2022
Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapyYue Huang, Houli Zhao, Mi Shao, et al.
Cancer Biology & Therapy|September 19, 2024
The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patientsLinlin Huang, Yi Zhong, Qingxiao Chen, et al.
Oncotarget|June 23, 2016
Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft modelsDonghua He, Xing Guo, Enfan Zhang, et al.
Diabetologia|December 24, 2013
Role for sterol regulatory element binding protein-1c activation in mediating skeletal muscle insulin resistance via repression of rat insulin receptor substrate-1 transcriptionYan Bi, Wenjun Wu, Junfeng Shi, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|July 23, 2018
Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma CellsYi Zhao, Enfan Zhang, Ning Lv, et al.
Frontiers in Pharmacology|December 28, 2020
Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World DataJingsong He, Donghua He, Xiaoyan Han, et al.
Cancer Medicine|May 3, 2024
Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in ChinaXiaoyan Han, Xincheng Jiang, Jingsong He, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|December 8, 2022
The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patientsDonghua He, Chunting Zhu, Xing Guo, et al.
Cell Death & Disease|November 3, 2017
BAFF is involved in macrophage-induced bortezomib resistance in myelomaJing Chen, Donghua He, Qingxiao Chen, et al.
Frontiers in Oncology|July 1, 2021
Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Date in ChinaXiaoyan Han, Chunxiang Jin, Gaofeng Zheng, et al.
Pageof 46

Showing results (361-370 of 454) with videos related to

Sort By:
Pageof 46
Bone Marrow Transplantation|June 1, 2022
Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapyYue Huang, Houli Zhao, Mi Shao, et al.
Cancer Biology & Therapy|September 19, 2024
The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patientsLinlin Huang, Yi Zhong, Qingxiao Chen, et al.
Oncotarget|June 23, 2016
Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft modelsDonghua He, Xing Guo, Enfan Zhang, et al.
Diabetologia|December 24, 2013
Role for sterol regulatory element binding protein-1c activation in mediating skeletal muscle insulin resistance via repression of rat insulin receptor substrate-1 transcriptionYan Bi, Wenjun Wu, Junfeng Shi, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|July 23, 2018
Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma CellsYi Zhao, Enfan Zhang, Ning Lv, et al.
Frontiers in Pharmacology|December 28, 2020
Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World DataJingsong He, Donghua He, Xiaoyan Han, et al.
Cancer Medicine|May 3, 2024
Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in ChinaXiaoyan Han, Xincheng Jiang, Jingsong He, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|December 8, 2022
The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patientsDonghua He, Chunting Zhu, Xing Guo, et al.
Cell Death & Disease|November 3, 2017
BAFF is involved in macrophage-induced bortezomib resistance in myelomaJing Chen, Donghua He, Qingxiao Chen, et al.
Frontiers in Oncology|July 1, 2021
Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Date in ChinaXiaoyan Han, Chunxiang Jin, Gaofeng Zheng, et al.
Pageof 46